News
TRVI
17.96
-1.59%
-0.29
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Seeking Alpha · 3d ago
Weekly Report: what happened at TRVI last week (0810-0814)?
Weekly Report · 6d ago
Trevi Therapeutics Price Target Raised to $28.00/Share From $24.00 by Jones Trading
Dow Jones · 08/14 13:01
Trevi Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 08/14 13:01
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Benzinga · 08/14 12:52
Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
TipRanks · 08/13 19:35
Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target
TipRanks · 08/11 10:15
Weekly Report: what happened at TRVI last week (0803-0807)?
Weekly Report · 08/10 09:06
Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged
TipRanks · 08/07 21:35
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 08/07 15:31
Trevi Therapeutics Price Target Raised to $25.00/Share From $24.00 by Oppenheimer
Dow Jones · 08/07 15:31
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25
Benzinga · 08/07 15:21
Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley
TipRanks · 08/07 13:57
Trevi Therapeutics price target raised to $40 from $27 at Raymond James
TipRanks · 08/07 13:37
Morgan Stanley Remains a Buy on Trevi Therapeutics (TRVI)
TipRanks · 08/07 12:26
Trevi Therapeutics Price Target Raised to $30.00/Share From $25.00 by Cantor Fitzgerald
Dow Jones · 08/07 12:18
Trevi Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 08/07 12:18
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30
Benzinga · 08/07 12:09
Trevi Therapeutics GAAP EPS of -$0.11 in-line
Seeking Alpha · 08/06 20:24
Press Release: Trevi Therapeutics Reports Second -2-
Dow Jones · 08/06 20:05
More
Webull provides a variety of real-time TRVI stock news. You can receive the latest news about Trevi Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.